The U.S. Food and Drug Administration took another action against Ranbaxy Laboratories Ltd. on Thursday, prohibiting it from making or selling drug ingredients from its Toansa, India, plant for the U.S. market.. Ranbaxy, an Indian unit of Japan's Daiichi Sankyo Co., has been a major supplier of drug ingredients to the U.S.—especially for generic drugs—but has come under FDA scrutiny of late.. The...
  